DoP is implementing PLI Scheme for Pharma with total financial outlay of Rs 15,000 crore: MoS for Chemicals and Fertilizers

New Delhi: The Department of Pharmaceuticals is implementing the Production Linked Incentive (PLI) Scheme for Pharmaceuticals with a total financial outlay of Rs. 15,000 crore and scheme tenure up to FY 2027-28.

This was stated by the Union Minister of State for Chemicals and Fertilizers Smt Anupriya Patel in Lok Sabha in reply to a question.

The scheme provides for financial incentive to 55 selected applicants for manufacturing of identified products under three categories for a period of six years. The product Category 1 covers drugs such as bio-pharmaceuticals, complex generics, gene therapy drugs, complex excipients, orphan drugs etc. Orphan drugs are those drugs which are used for treatment of rare diseases. Under the scheme, total 8 orphan drugs have been approved for manufacturing, the Minister further added.

The 8 orphan drugs approved include Nitisinone indicated for treatment of Hereditary Tyrosinemia Type 1, Cannabidiol indicated for Dravet-Lennox Gastaut syndrome, Nusinersen to treat Spinal Muscular Atrophy.

The orphan drugs approved under the PLI scheme for Pharmaceuticals are as follows: